Kaitlin Kestenberg-Messina Sells 10,096 Shares of ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics Inc (NASDAQ:ADMA) COO Kaitlin Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ADMA Biologics Trading Down 1.0%

Shares of ADMA stock opened at $15.67 on Thursday. The business’s 50 day moving average is $16.75 and its two-hundred day moving average is $16.74. ADMA Biologics Inc has a twelve month low of $13.76 and a twelve month high of $25.67. The company has a market capitalization of $3.73 billion, a P/E ratio of 26.12 and a beta of 0.51. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. During the same quarter in the previous year, the company posted $0.46 earnings per share. The company’s revenue for the quarter was up 18.4% compared to the same quarter last year. Equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on ADMA shares. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Finally, Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, ADMA Biologics has an average rating of “Buy” and a consensus target price of $32.00.

Institutional Trading of ADMA Biologics

Hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC boosted its stake in shares of ADMA Biologics by 58.0% in the fourth quarter. Corient Private Wealth LLC now owns 91,367 shares of the biotechnology company’s stock valued at $1,667,000 after buying an additional 33,541 shares in the last quarter. Vident Advisory LLC raised its position in ADMA Biologics by 24.2% in the fourth quarter. Vident Advisory LLC now owns 270,492 shares of the biotechnology company’s stock worth $4,934,000 after acquiring an additional 52,687 shares in the last quarter. First Citizens Bank & Trust Co. raised its position in ADMA Biologics by 24.4% in the fourth quarter. First Citizens Bank & Trust Co. now owns 48,763 shares of the biotechnology company’s stock worth $889,000 after acquiring an additional 9,576 shares in the last quarter. Cim LLC lifted its holdings in ADMA Biologics by 3.2% in the fourth quarter. Cim LLC now owns 94,379 shares of the biotechnology company’s stock valued at $1,721,000 after acquiring an additional 2,893 shares during the period. Finally, nVerses Capital LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at $395,000. 75.68% of the stock is owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.